New shot cuts bleeding in hemophilia a patients

NCT ID NCT03315455

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested emicizumab (Hemlibra) in 85 people with hemophilia A, a condition where blood doesn't clot properly, causing frequent bleeds. Participants received either emicizumab injections or no preventive treatment. The study found that those on emicizumab had significantly fewer bleeding episodes, suggesting it could be a valuable option for managing the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: emicizumab (Hemlibra)
What this could lead to: If successful, this could provide a more convenient and effective way to prevent bleeding episodes in people with hemophilia A, reducing the need for frequent intravenous treatments.
What could go wrong: The trial is completed and results are positive, but long-term safety and effectiveness in broader populations still need monitoring. Some patients may still experience breakthrough bleeds or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Locations

Beijing Children's Hospital, Capital Medical University

Beijing, 100045, China
Peking Union Medical College Hospital

Beijing, 100730, China
Penang General Hospital

George Town, Pulau Pinang, 10990, Malaysia
Prince of Wales Hospital

Shatin, Hong Kong
Queen Elizabeth Hospital

Sabah, Sabah, 88586, Malaysia
Queen Mary Hospital

Hong Kong, Hong Kong
Ramathibodi Hospital

Bangkok, 10400, Thailand
Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai, 200025, China
Southern Medical University Nanfang Hospital

Guangdong Province Guangzhou City, 510515, China
Tianjin Institute of Hematology & Blood Diseases Hospital

Tianjin, 300020, China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech

Wuhan, 430030, China
Xiangya Hospital of Centre-South University

Changsha, 410008, China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

Wuhan, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.